ArticleFrontiers in aging neuroscience2026
Association of cerebrospinal fluid amphiphysin-1 levels with cognition and Alzheimer's disease pathology biomarkers.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Amphiphysin-1 (AMPH), an accessory component of the clathrin-mediated endocytosis (CME) machinery, plays a critical role in synaptic vesicle recycling and membrane dynamics and has been implicated in Alzheimer's disease (AD) risk. However, its relationship with core AD biomarkers and disease progression remains unclear. Methods: In this study, we examined the associations between cerebrospinal fluid (CSF) AMPH and core AD biomarkers (CSF amyloid-β42 [Aβ Results: AMPH exhibited stage-dependent alterations across the AD continuum, characterized by lower levels in stage 1, and elevated levels in stage 2 and SNAP. Cross-sectionally, CSF AMPH was positively associated with core CSF biomarkers. Longitudinal analyses showed that, among amyloid-negative individuals, higher baseline AMPH was associated with faster decreases in CSF Aβ Discussion: In ADNI, CSF AMPH was associated with biological changes across the AD continuum, cognitive decline, hippocampal atrophy, and clinical progression. These findings may provide complementary information for understanding disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.